Purdue Pharma LP

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1892-01-01

Employees: 5K

Market Cap: -

Website: http://www.purduepharma.com

Clinical Trials

Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain

Phase 3

Withdrawn

Conditions: Other Acute Postoperative Pain
Prolonged Endotracheal Intubation

Interventions: Drug: Buprenorphine IV

First Posted Date: 2011-03-29

Last Posted Date: 2016-02-04

Lead Sponsor: Purdue Pharma LP

Registration Number: NCT01324544

Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Buprenorphine transdermal system

First Posted Date: 2011-03-29

Last Posted Date: 2017-07-06

Lead Sponsor: Purdue Pharma LP

Target Recruit Count: 41

Registration Number: NCT01324570

Locations: 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Willis-Knighton Physician Network, Shreveport, Louisiana, United States
🇺🇸
Howard University Hospital, Washington, D.C., District of Columbia, United States

and more 19 locations

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Buprenorphine transdermal patch

First Posted Date: 2010-12-13

Last Posted Date: 2012-09-03

Lead Sponsor: Purdue Pharma LP

Target Recruit Count: 70

Registration Number: NCT01259102

Locations: 🇺🇸
The Ohio State University Department of Pharmacology, Columbus, Ohio, United States

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Buprenorphine transdermal patch
Drug: Ketoconazole tablet
Drug: Placebo to match ketoconazole tablet

First Posted Date: 2010-12-13

Last Posted Date: 2014-05-19

Lead Sponsor: Purdue Pharma LP

Target Recruit Count: 20

Registration Number: NCT01259115

Locations: 🇺🇸
Clinical Research Center, New Orleans, Louisiana, United States

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Oxycodone HCl controlled-release tablets

First Posted Date: 2010-09-01

Last Posted Date: 2020-03-23

Lead Sponsor: Purdue Pharma LP

Target Recruit Count: 155

Registration Number: NCT01192295

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Research Facility, The Woodlands, Texas, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States

and more 44 locations

Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients

Phase 1

Completed

Conditions: Opioid Analgesia

Interventions: Drug: Oxycodone hydrochloride controlled-release (ORF) tablets

First Posted Date: 2010-07-12

Last Posted Date: 2012-10-15

Lead Sponsor: Purdue Pharma LP

Target Recruit Count: 30

Registration Number: NCT01160614

Locations: 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States
🇺🇸
Research Facility, Miami, Florida, United States
🇺🇸
LS Packard Children's Hospital, Palo Alto, California, United States

and more 14 locations

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

Phase 3

Completed

Conditions: Chronic Nonmalignant Pain

Interventions: Drug: Buprenorphine transdermal patch

First Posted Date: 2010-06-25

Last Posted Date: 2012-09-10

Lead Sponsor: Purdue Pharma LP

Target Recruit Count: 189

Registration Number: NCT01151098

Locations: 🇺🇸
University Clinical Research Deland, Deland, Florida, United States
🇺🇸
Pain Management & Rehabilitation, Terre Haute, Indiana, United States
🇺🇸
Arizona Research Center Inc., Phoenix, Arizona, United States

and more 16 locations

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Buprenorphine transdermal patch
Drug: Matching placebo transdermal patch
Drug: Avelox (moxifloxacin hydrochloride) tablet

First Posted Date: 2010-06-22

Last Posted Date: 2012-09-03

Lead Sponsor: Purdue Pharma LP

Target Recruit Count: 132

Registration Number: NCT01148537

Locations: 🇺🇸
PPD Development, LP, Clinics, Austin, Texas, United States

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

Phase 3

Completed

Conditions: Osteoarthritis

Interventions: Drug: Buprenorphine transdermal patch

First Posted Date: 2010-06-10

Last Posted Date: 2012-09-03

Lead Sponsor: Purdue Pharma LP

Target Recruit Count: 290

Registration Number: NCT01141283

Locations: 🇺🇸
Arthrocare, Arthritis Care and Research, Phoenix, Arizona, United States
🇺🇸
Great Lakes Family Care, Cadillac, Michigan, United States
🇺🇸
Arizona Research Center, Phoenix, Arizona, United States

and more 18 locations

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

Phase 3

Terminated

Conditions: Osteoarthritis

Interventions: Drug: Buprenorphine transdermal patch

First Posted Date: 2010-06-02

Last Posted Date: 2012-09-10

Lead Sponsor: Purdue Pharma LP

Target Recruit Count: 196

Registration Number: NCT01135524

Locations: 🇺🇸
HealthCare Research LLC, St. Louis, Missouri, United States
🇺🇸
Louisville Endocrinology PSC, Louisville, Kentucky, United States
🇺🇸
Alabama Neurology and Pain Medicine, Alabaster, Alabama, United States

and more 23 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy